Oxford Drug Design has announced new in vivo results that further validate its emerging first‑in‑class oncology programme, ...

Cellistic has unveiled three new GMP manufacturing platforms designed to advance iPSC-derived cell therapies across ...

Ipsen has announced the presentation of new study data on Dysport (abobotulinumtoxinA) in stroke and other neurological ...

Nuclera has expanded its Series C funding round to USD $87 million following a new USD $12 million extension led by Elevage ...

Fabentech has received Marketing Authorisation in France for Ricimed, an antidote designed to treat ricin poisoning, marking ...

The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...

PMGroup Worldwide Ltd are pleased to announce their acquisition of the MAD World Summit and conference. This strategic ...

Berendsen most recently served as Vice President of Finance and Control at Royal Reesink; his expertise in financial ...

HUTCHMED has advanced its ongoing study of surufatinib and camrelizumab for treatment‑naïve metastatic pancreatic ductal ...

Zenas BioPharma has announced positive findings from its phase 3 INDIGO trial evaluating obexelimab in patients with ...

Bial has introduced a new sublingual formulation of apomorphine in the UK, offering a fresh treatment option for adults with Parkinson’s disease who experience intermittent OFF episodes that are not ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.